8-K 1 a06-6731_18k.htm CURRENT REPORT OF MATERIAL EVENTS OR CORPORATE CHANGES

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): March 9, 2006

 

AMYLIN PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware

 

0-19700

 

33-0266089

(State or other jurisdiction

 

(Commission

 

(IRS Employer

of incorporation)

 

File Number)

 

Identification No.)

 

9360 Towne Centre Drive

 

 

San Diego, California

 

92121

(Address of principal executive offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code:  (858) 552-2200

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 


 

Item 8.01 Other Events.

 

Effective March 9, 2006, Amylin Pharmaceuticals, Inc. implemented a price increase for BYETTA® (exenatide) injection and SYMLIN® (pramlintide acetate) injection.  The wholesale acquisition cost for a 5 microgram per dose pen of BYETTA increased from $147.00 to $155.82, and the wholesale acquisition cost for a 10 microgram per dose pen of BYETTA increased from $172.50 to $182.85.   The wholesale acquisition cost for SYMLIN increased from $79.50 per vial to $85.86 per vial.

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

AMYLIN PHARMACEUTICALS, INC.

 

 

 

Dated: March 10, 2006

By:

/S/ LLOYD A. ROWLAND

 

 

Lloyd A. Rowland

 

 

Vice President, Legal, General Counsel and

 

 

Secretary

 

2